Classical Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Classical Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating magrolimab plus pembrolizumab in relapsed or refractory classic Hodgkin lymphoma has been terminated with results p…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers [Phase 1]
Phase 1 clinical trial update for PF-08046032 in people with advanced cancers; the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents [Phase 3]
This clinical trial update reports the completion of a Phase 3 international inter-group study evaluating treatment for Classical Hodgkin Ly…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment [Phase 2, Phase 3]
A multinational Phase 2/3 trial is studying Brentuximab Vedotin as initial therapy for newly diagnosed classical Hodgkin lymphoma in Chinese…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating Brentuximab Vedotin as consolidation therapy after allogeneic stem cell transplantation in relapsed or refractory c…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 3]
Completed Phase 3 clinical trial evaluating a bendamustine/gemcitabine/vinorelbine regimen in relapsed/refractory classical Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 3]
Phase 3 trial comparing tislelizumab monotherapy to salvage chemotherapy in relapsed/refractory Classical Hodgkin lymphoma; the study has be…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) [Phase 3]
This update reports the completion of a Phase 3 trial (MK-3475-204/KEYNOTE-204) comparing pembrolizumab to brentuximab vedotin in relapsed o…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]
Phase 2 trial update evaluating the combination of ibrutinib and nivolumab for relapsed or refractory classical Hodgkin lymphoma, sponsored …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating A(B)VD chemotherapy followed by Nivolumab as frontline therapy for higher-risk classical Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) [Phase 2]
Phase 2 study evaluating pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in relapsed or refractory classical Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma [Phase 2]
This entry describes a Phase 2 clinical trial evaluating camrelizumab in combination with AVD as first-line therapy for patients with advanc…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
This trial is investigating the use of circulating tumor DNA as a non-invasive biomarker to monitor therapy in pediatric classical Hodgkin l…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma [NA]
This completed clinical trial examines recurrent XPO1 mutations and their prognostic value in patients with Classical Hodgkin Lymphoma.
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. [Phase 2]
A Phase 2 clinical trial evaluating chidamide and decitabine in combination with an anti-PD-1 antibody for relapsed/refractory classical Hod…
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]
A Phase 2 trial evaluating tislelizumab in relapsed or refractory classical Hodgkin lymphoma has completed, and results have been posted.
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of brentuximab vedotin and nivolumab for relapsed/refractory classical Hodgkin lymphoma;…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating the combination of nivolumab and ipilimumab in adults with HIV-associated relapsed or refractory classical Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A first-in-human phase 1/2 trial of GEN3017 in classical Hodgkin lymphoma and non-Hodgkin lymphoma was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma [NA]
ClinicalTrials.gov reports a completed frontline trial comparing Brentuximab Vedotin with AVD versus ABVD chemotherapy in patients with adva…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors [Phase 2]
Phase 2 clinical trial investigating the combination of Brentuximab Vedotin and Nivolumab for relapsed/refractory classical Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of gemcitabine, bendamustine, and nivolumab in relapsed or refractory classical Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2025-07-20Clinical Trial Update: Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas [Phase 1]
Phase 1 clinical trial evaluating allogeneic CD30.CAR-EBVSTs in relapsed or refractory CD30-positive lymphomas, currently recruiting.